Evidence map›Paper›PMID 33955828›Full record

ArticleTissue barriers2021

HDAC inhibitor, MS-275, increases vascular permeability by suppressing Robo4 expression in endothelial cells.

Taito Kashio, Keisuke Shirakura, Mayumi Kinoshita, Maaya Morita, Ryosuke Ishiba, Kosuke Muraoka, Tomoaki Kanbara, Masato Tanaka, Risa Funatsu, Nobumasa Hino and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Tissue barriers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. The RANK/RANKL axis controls vascular dynamics in the bone marrow.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Taito KashioGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Keisuke ShirakuraGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Mayumi KinoshitaGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Maaya MoritaGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Ryosuke IshibaGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Kosuke MuraokaGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Tomoaki KanbaraGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Masato TanakaGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Risa FunatsuGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Nobumasa HinoGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Shohei KoyamaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Ryo SuzukiLaboratory of Drug and Gene Delivery Research, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan.
Yasuo YoshiokaGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Taiki AoshiDepartment of Cellular Immunology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Takefumi DoiGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Yoshiaki OkadaGraduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.ORCID 0000-0002-2962-244X
Osaka University of Pharmaceutical Sciences · JPThe University of Osaka · JPKyoto Biken Laboratories (Japan) · JPTeikyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Roundabout guidance receptor 4 (Robo4) is an endothelial-specific membrane protein that suppresses pathological angiogenesis and vascular hyperpermeability by stabilizing endothelial cells. Robo4 suppresses severe systemic inflammation induced by pathogens and endotoxins and inhibits tumor growth and metastasis, therefore serving as a potential therapeutic target. Although the regulation of Robo4 expression through transcription factors and epigenetic mechanisms has been studied, the role of histone deacetylases (HDACs) has not been explored. In the present study, we investigated the involvement of HDACs in the regulation of Robo4 expression. An HDAC inhibitor, MS-275, which inhibits HDAC1, HDAC2, and HDAC3, was found to suppress Robo4 expression in endothelial cells. Small interfering RNA (siRNA)-mediated knockdown of HDAC3, but not of HDAC1 and 2, also decreased its expression level. MS-275 downregulated the expression of the transcription factor complex GABP, in addition to suppressing Robo4 promoter activity. GABP expression was also downregulated by the siRNA against HDAC3. MS-275 decreased the transendothelial electrical resistance of a monolayer of mouse endothelial cells and increased the rate of leakage of Evans blue dye in the mouse lungs. In addition, MS-275 accelerated cell migration through the endothelial cell monolayer and augmented cell extravasation in the mouse lungs. Taken together, we demonstrated that MS-275 suppresses Robo4 expression by inhibiting HDAC3 in endothelial cells and enhances endothelial and vascular permeability. Thus, we demonstrated a novel mechanism regulating Robo4 expression and vascular permeability, which is anticipated to contribute to future therapies for infectious and inflammatory diseases.

Indexed as

Capillary PermeabilityEndothelial CellsAnimalsBenzamidesHistone Deacetylase InhibitorsMicePyridinesReceptors, Cell SurfaceBenzamidesentinostatHistone Deacetylase InhibitorsPyridinesReceptors, Cell SurfaceRobo4 protein, mouseadherens junctionendothelial cellsHDAC3MS-275roundabout 4

Identifiers

PMID33955828
PMCPMC8489956
OpenAlexW3159656252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.